Urology

The genito urinary cancer group at The Christie is one of the most advanced urological cancer teams in the country. This multi-disciplinary group combines specialist urological cancer surgeons with uroradiotherapists, specialist medical oncologists, urological cancer nurses and a comprehensive research team for the management of all urological cancers and for research in to genito-urinary malignancy.

There is specific expertise for dealing with conventional and complex kidney (renal), bladder, prostate, penile and testicular cancers and published outcomes from treatment are amongst the best in the UK. All modalities of treatment are available for these cancer types and since January 2008, the Da Vinci operating robot has been in service for the treatment of localised prostate cancer using robotic laparoscopic techniques. This is the only instrument of its type in the North West of England.

In addition to this, the urological team is a key member of the integrated Christie "Pelvic Team". This multi-disciplinary group provides advanced surgical expertise for the diagnosis and treatment for patients with ultra-complex or advanced pelvic tumours of both gynaecological, large bowel and sarcomatous origin. The team accepts referrals from local regional national and international sources.

Conditions Treated:

Kidney, adrenal, bladder, prostate, urethral, penile, testicular, retro-peritoneal and pelvic sarcoma.

Robotic Prostatectomy:

Since January 2008, the Da Vinci operating robot has been in service for the treatment of localised prostate cancer. Robotic prostatectomy involves the surgeon making 5-6 small openings (ports) in the abdominal wall that measure 1-2cm. These small openings in the tummy then facilitate the insertion of very sophisticated robotic instruments that are extremely manoeuvrable, apart from being small in size.

The surgeon sitting at a console then controls these instruments to carry out the operation. The significantly enhanced magnification, scaling and precise movement of the instruments allow the surgery to be carried out with reduced blood loss, reduced pain and discomfort than routine surgery. Apart from facilitating the precise nature of the operation, it allows a faster recovery time.

The whole theatre team, including theatre sisters, anaesthetist and two surgeons (Mr Ramani and Mr Lau) have received training in several different centres in the USA and Europe. Apart from this, the surgeons were also mentored by other surgeons who had been carrying out this procedure previously. We have not had to convert any patient to an open operation and the length of stay has been less than three days. No patient has needed a blood transfusion and the early outcomes have been very promising.

Who to contact

Surgeons:

  • Professor Noel Clarke, professor of urological oncology
  • Mr Vijay Ramani, consultant surgeon in urological oncology
  • Mr Vijay Sangar, consultant surgeon in urological oncology
  • Mr Maurice Lau, consultant surgeon in urological oncology

Clinical oncologists:

  • Dr Richard Cowan (bladder/prostate)
  • Dr Ananya Choudhury (bladder/prostate)
  • Dr Tony Elliott (bladder/prostate/penile)
  • Dr John Logue (bladder/prostate/testis)
  • Dr Jac Livsey (bladder/prostate/gynaecology)
  • Dr James Wylie (bladder/prostate/sarcoma)
  • Dr Richard Welch (testis)

Medical oncologists:

  • Professor Robert Hawkins (renal/adrenal)
  • Dr Michael Leahy (testis/sarcoma)

Specialist nurses:

  • Ms Jane Booker, Macmillan urology clinical nurse specialist
  • Mrs Catherine Gwatkin, Macmillan urology clinical nurse specialist
  • Ms Sinead Collins, Advanced nurse practitioner

Research nurses:

  • Damian McCaul, research nurse manager
  • Vivian Thomas, research nurse
  • Catherine Redshaw, research nurse.

Chief scientist:

  • Dr Mick Brown

Contact tel: 0161 446 3363 or 0161 446 3364

Patient booklets can be found in our patient information booklet database

< Back to Surgery